| A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
Alkaline Phosphatase
MessagePerformed in Chemistry
Test Code
ALKP
CPT Codes
84075
Preferred Specimen
Green Top LiHep, Plasma
WyMCC - SST
WyMCC - SST
Other Acceptable Specimens
Gold/SST, Red Top
Transport Temperature
Refrigerated
Reject Criteria (Eg, hemolysis? Lipemia? Thaw/Other?)
Hemolysis
FDA Status
FDA Approved
Setup Schedule
Daily, Sunday through Saturday
Report Available
Less than 4 hours
Clinical Significance
Alkaline phosphatase in serum consists of four structural genotypes: liver-bonekidney type, intestinal type, placental type and variant from germ cells. It occurs in osteoblasts, hepatocytes, leukocytes, kidneys, spleen, placenta, prostate and small intestine. The liver-bone-kidney type is particularly important.
A rise in the alkaline phosphatase occurs with all forms of cholestasis, particularly with obstructive jaundice. It is also elevated in diseases of the skeletal system, such as Paget’s disease, hyperparathyroidism, rickets and osteomalacia, as well as with fractures and malignant tumors. Considerable rise in alkaline phosphatase activity is sometimes seen in children and juveniles. It is caused by increased osteoblast activity following accelerated bone growth.
The assay method was first described by King and Armstrong, modified by Ohmori, Bessey, Lowry and Brock and later improved by Hausamen et al. In 1983 the International Federation of Clinical Chemistry (IFCC) recommended a standardized method for the determination of alkaline phosphatase using an optimized substrate concentration and 2-amino-2-methyl-1-propanol as buffer plus the cations magnesium and zinc. The assay described here is based on this recommendation, but was optimized for performance and stability. The assay was standardized against the IFCC reference formulation proposed above.
A rise in the alkaline phosphatase occurs with all forms of cholestasis, particularly with obstructive jaundice. It is also elevated in diseases of the skeletal system, such as Paget’s disease, hyperparathyroidism, rickets and osteomalacia, as well as with fractures and malignant tumors. Considerable rise in alkaline phosphatase activity is sometimes seen in children and juveniles. It is caused by increased osteoblast activity following accelerated bone growth.
The assay method was first described by King and Armstrong, modified by Ohmori, Bessey, Lowry and Brock and later improved by Hausamen et al. In 1983 the International Federation of Clinical Chemistry (IFCC) recommended a standardized method for the determination of alkaline phosphatase using an optimized substrate concentration and 2-amino-2-methyl-1-propanol as buffer plus the cations magnesium and zinc. The assay described here is based on this recommendation, but was optimized for performance and stability. The assay was standardized against the IFCC reference formulation proposed above.
Performing Laboratory
system
